Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
Portfolio Pulse from
Clearmind Medicine Inc. has signed a non-binding term sheet with Dr. Glitter Pty Ltd to develop a novel psychedelic MEAI-based alcohol substitute using ActivCrystal™ technology. This collaboration aims to commercialize Clearmind's alcohol substitute in a unique oral delivery format.
December 16, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clearmind Medicine Inc. has entered into a non-binding agreement with Dr. Glitter Pty Ltd to develop a MEAI-based alcohol substitute using ActivCrystal™ technology. This partnership could enhance Clearmind's product offerings and market reach.
The partnership with Dr. Glitter Pty Ltd could lead to the development of a unique product that combines Clearmind's MEAI-based alcohol substitute with ActivCrystal™ technology. This could potentially open new markets and increase Clearmind's product offerings, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90